Advertisement
AMGN vs GSK
Which Stock Would AI Choose? Amgen (AMGN) vs. GSK plc (GSK) Stock Comparison
Key Takeaways
- Amgen (AMGN) reported first-quarter 2026 revenues of $8.6 billion, reflecting 6% year-over-year growth driven by volume increases across key therapeutic areas.
- GSK plc (GSK) received U.S. FDA approval in July 2026 for its lung cancer treatment Jideytro, marking entry into a new oncology segment following a major acquisition.
- Both companies operate in the healthcare sector with exposure to innovative medicines, though Amgen emphasizes cardiovascular, bone health, and respiratory products while GSK focuses on vaccines, respiratory, and oncology.
- Recent market activity shows GSK benefiting from positive regulatory news, while Amgen continues steady execution on its 2026 revenue guidance range of $37.1 billion to $38.5 billion.
- Share buyback programs and pipeline advancements represent key contrasts, with GSK actively repurchasing shares and Amgen highlighting multiple growth drivers through the end of the decade.
- Relative performance reflects sector dynamics, with both stocks influenced by clinical trial outcomes, regulatory decisions, and broader biotech/pharma sentiment over recent weeks.
Introduction
This comparison examines Amgen (AMGN) and GSK plc (GSK), two established pharmaceutical companies with distinct portfolios in biotechnology and global healthcare. Investors and traders focused on healthcare sector exposure, dividend stability, and pipeline catalysts may find the analysis relevant for assessing relative positioning. The review highlights observable differences in business models, recent momentum, and market factors without forecasting outcomes.
AMGN Overview and Recent Performance
Amgen (AMGN) is a leading biotechnology company specializing in therapies for serious illnesses, including oncology, cardiovascular disease, and inflammation. In recent weeks, the stock has reflected ongoing execution of its growth strategy, supported by first-quarter 2026 financial results that showed total revenues rising 6% to $8.6 billion. Product sales grew 4%, aided by volume gains in established franchises. Management outlined six long-term growth drivers spanning cardiovascular, bone health, and respiratory areas, with biosimilars contributing notably to performance. Broader market activity has been influenced by pipeline updates and full-year 2026 guidance projecting revenues between $37.1 billion and $38.5 billion.
GSK Overview and Recent Performance
GSK plc (GSK) is a global pharmaceutical company with strengths in vaccines, respiratory medicines, and oncology. Recent market activity has centered on regulatory and pipeline developments, including U.S. FDA approval in July 2026 for Jideytro to treat a form of lung cancer. The approval followed a significant acquisition and provided a near-term catalyst. The company has also continued its share buyback program, repurchasing millions of shares in recent months. Second-quarter 2026 earnings are scheduled for late July, with prior quarterly updates showing solid performance in core areas. Sentiment has been shaped by both positive approvals and select late-stage trial outcomes in other indications.
Trending AI Robots
Tickeron maintains a curated section called Trending AI Robots that features select AI trading bots optimized for prevailing market conditions. The platform offers hundreds of AI Trading Bots capable of trading thousands of different tickers across varied strategies, timeframes, and performance profiles. Only the most suitable bots, based on metrics such as consistency and adaptability, are highlighted in this trending section. Available bots span different trading styles and statistics, providing users with options tailored to specific objectives. For additional details on these tools, visit Trending AI Robots.
Head-to-Head Comparison
Amgen (AMGN) and GSK plc (GSK) differ in their core business emphases: Amgen concentrates on biotechnology-driven innovation in areas such as cardiovascular and bone health, whereas GSK maintains broader exposure to vaccines and respiratory products alongside emerging oncology assets. Recent momentum favors GSK following its FDA approval for Jideytro, while Amgen has demonstrated consistent revenue expansion and multiple organic growth drivers. Risk factors include clinical trial variability for both, with GSK navigating select development setbacks and Amgen managing guidance execution in a competitive environment. Sector exposure places both within healthcare, though Amgen’s biotechnology focus may imply different volatility patterns compared with GSK’s diversified pharmaceutical model. Market sentiment reflects these contrasts, with regulatory news providing clearer near-term visibility for one name and steady operational metrics supporting the other.
Tickeron AI Verdict
Based on observable factors including recent regulatory catalysts, trend consistency, and pipeline positioning, Tickeron’s AI models would currently assign a higher probability of favorable relative performance to GSK plc (GSK) over the near term. This assessment draws from the July 2026 FDA approval and active share repurchase activity, balanced against Amgen’s (AMGN) demonstrated revenue growth and guidance adherence. Outcomes remain subject to broader market variables and further data releases.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a StrongBuy and GSK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green whileGSK’s FA Score has 1 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- GSK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 4 TA indicator(s) are bullish while GSK’s TA Score has 5 bullish TA indicator(s).
- AMGN’s TA Score: 4 bullish, 4 bearish.
- GSK’s TA Score: 5 bullish, 4 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +2.43% price change this week, while GSK (@Pharmaceuticals: Major) price change was +0.66% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.41%. For the same industry, the average monthly price growth was -2.13%, and the average quarterly price growth was +3.17%.
Reported Earning Dates
AMGN is expected to report earnings on Aug 04, 2026.
GSK is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.41% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | GSK | AMGN / GSK | |
| Capitalization | 208B | 104B | 200% |
| EBITDA | 16.7B | 10.1B | 165% |
| Gain YTD | 19.384 | 7.222 | 268% |
| P/E Ratio | 26.80 | 16.41 | 163% |
| Revenue | 37.2B | 32.8B | 113% |
| Total Cash | 12B | 3.44B | 349% |
| Total Debt | 57.3B | 19.1B | 300% |
AMGN | GSK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 64 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 16 | 42 | |
SMR RATING 1..100 | 12 | 27 | |
PRICE GROWTH RATING 1..100 | 19 | 48 | |
P/E GROWTH RATING 1..100 | 52 | 53 | |
SEASONALITY SCORE 1..100 | 50 | 55 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (10) in the Biotechnology industry is significantly better than the same rating for GSK (78) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than GSK’s over the last 12 months.
AMGN's Profit vs Risk Rating (16) in the Biotechnology industry is in the same range as GSK (42) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to GSK’s over the last 12 months.
AMGN's SMR Rating (12) in the Biotechnology industry is in the same range as GSK (27) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to GSK’s over the last 12 months.
AMGN's Price Growth Rating (19) in the Biotechnology industry is in the same range as GSK (48) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to GSK’s over the last 12 months.
AMGN's P/E Growth Rating (52) in the Biotechnology industry is in the same range as GSK (53) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to GSK’s over the last 12 months.
| AMGN | GSK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 59% | N/A |
| Stochastic ODDS (%) | 2 days ago 50% | 1 day ago 63% |
| Momentum ODDS (%) | 2 days ago 53% | 1 day ago 44% |
| MACD ODDS (%) | 2 days ago 65% | 1 day ago 73% |
| TrendWeek ODDS (%) | 2 days ago 61% | 1 day ago 64% |
| TrendMonth ODDS (%) | 2 days ago 59% | 1 day ago 49% |
| Advances ODDS (%) | 4 days ago 59% | 4 days ago 62% |
| Declines ODDS (%) | 12 days ago 51% | 1 day ago 54% |
| BollingerBands ODDS (%) | 2 days ago 50% | 1 day ago 48% |
| Aroon ODDS (%) | 2 days ago 54% | 1 day ago 55% |
Advertisement
AMGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with BIIB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | -0.64% | ||
| BIIB - AMGN | 62% Loosely correlated | N/A | ||
| PFE - AMGN | 52% Loosely correlated | +0.40% | ||
| GILD - AMGN | 52% Loosely correlated | N/A | ||
| MRK - AMGN | 50% Loosely correlated | +0.32% | ||
| ABBV - AMGN | 47% Loosely correlated | -2.51% | ||
More | ||||